REGENXBIO Closes $370M+ Gene Therapy Eye Care Collaboration Agreement with AbbVie for Wet AMD and Diabetic Retinopathy

Published on :

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

REGENXBIO and Solid Biosciences Take Aim at Rare Diseases with AAV Gene Therapies via New Pathway Development Consortium

REGENXBIO Logo
Published on :

Rare disease specialist REGENXBIO is partnering with Solid Biosciences to advance AAV gene therapies for rare diseases through an accelerated approval pathway with the U.S. Food and Drug Administration.

A Unique Talent Pool is Propelling Philly to become a Top Biotech Cluster

Published on :

As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.

Cell and Gene Therapy’s Future a Complex Mix of Promise and Pitfalls

Published on :

At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.

Rare Disease Challenge, REGENXBIO Tackles Duchenne Muscular Dystrophy

Published on :

Duchenne Muscular Dystrophy is a severe degenerative muscle disease that impacts about one in 5,000 boys per year across the globe. The disease causes a progressive loss of muscle strength attributable to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down.

2020’s Top 10 Most Read News Stories from the BioHealth Capital Region

Published on :

2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.

BioHealth Companies Selected for Prestigious Maryland Tech Council Annual Industry Awards

Published on :

The COVID-19 Pandemic didn’t stop the Maryland Tech Council from holding their 32nd Annual Industry awards. Taking this event online, MTC continued via a live virtual broadcast to recognize the top Life Sciences and Tech Companies in Maryland.

Maryland Biomanufacturing Leaders Discuss Challenges, Future Needs at 2020 Bio Innovation Conference

Published on :

The BioHealth Capital Region (BHCR) is known globally as a leading vaccine hub with nearly 20% of the world’s leading vaccine development influencers in Maryland, which is the heart of the BHCR.